HBIO

Company Overview — What Does HARVARD BIOSCIENCE INC Do?

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts. HARVARD BIOSCIENCE INC (HBIO) is classified as a micro-cap stock in the Technology sector, specifically within the Measuring And Control Equipment industry. The company is led by CEO James W. Green and employs approximately 490 people, headquartered in Wilmington, Massachusetts. With a market capitalization of $23M, HBIO is one of the notable companies in the Technology sector.

HARVARD BIOSCIENCE INC (HBIO) Stock Rating — Reduce (April 2026)

As of April 2026, HARVARD BIOSCIENCE INC receives a Reduce rating with a composite score of 37.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.HBIO ranks #1,983 out of 4,446 stocks in our coverage universe. Within the Technology sector, HARVARD BIOSCIENCE INC ranks #222 of 584 stocks, placing it in the upper half of its Technology peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

HBIO Stock Price and 52-Week Range

HARVARD BIOSCIENCE INC (HBIO) currently trades at $4.43. The stock lost $0.94 (17.5%) in the most recent trading session. The 52-week high for HBIO is $5.25, which means the stock is currently trading -15.6% from its annual peak. The 52-week low is $0.28, putting the stock 1475.9% above its annual trough. Recent trading volume was 429K shares, suggesting relatively thin trading activity.

Is HBIO Overvalued or Undervalued? — Valuation Analysis

HARVARD BIOSCIENCE INC (HBIO) carries a value factor score of 10/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.76x, versus the sector average of 3.16x. The price-to-sales ratio is 0.28x, compared to 1.06x for the average Technology stock. On an enterprise value basis, HBIO trades at 71.93x EV/EBITDA, versus 12.79x for the sector.

At current multiples, HARVARD BIOSCIENCE INC trades at a premium to most Technology peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

HARVARD BIOSCIENCE INC Profitability — ROE, Margins, and Quality Score

HARVARD BIOSCIENCE INC (HBIO) earns a quality factor score of 35/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -427.1%, compared to the Technology sector average of -1.4%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -73.3% versus the sector average of -1.0%.

On a margin basis, HARVARD BIOSCIENCE INC reports gross margins of 57.2%, compared to 50.9% for the sector. The operating margin is -59.9% (sector: -0.5%). Net profit margin stands at -67.5%, versus -1.5% for the average Technology stock. Revenue growth is running at -10.8% on a trailing basis, compared to 14.2% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

HBIO Debt, Balance Sheet, and Financial Health

HARVARD BIOSCIENCE INC has a debt-to-equity ratio of 261.0%, compared to the Technology sector average of 43.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 2.20x, indicating strong short-term liquidity. Total debt on the balance sheet is $36M. Cash and equivalents stand at $7M.

HBIO has a beta of 0.88, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for HARVARD BIOSCIENCE INC is 20/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

HARVARD BIOSCIENCE INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, HARVARD BIOSCIENCE INC reported revenue of $85M and earnings per share (EPS) of $-1.28. Net income for the quarter was $-59M. Gross margin was 57.2%. Operating income came in at $-52M.

In FY 2025, HARVARD BIOSCIENCE INC reported revenue of $87M and earnings per share (EPS) of $-1.28. Net income for the quarter was $-57M. Gross margin was 57.7%. Revenue grew -8.1% year-over-year compared to FY 2024. Operating income came in at $-49M.

In Q3 2025, HARVARD BIOSCIENCE INC reported revenue of $21M and earnings per share (EPS) of $-0.03. Net income for the quarter was $-1M. Gross margin was 58.4%. Revenue grew -6.3% year-over-year compared to Q3 2024. Operating income came in at $197,000.

In Q2 2025, HARVARD BIOSCIENCE INC reported revenue of $20M and earnings per share (EPS) of $-0.05. Net income for the quarter was $-2M. Gross margin was 56.4%. Revenue grew -11.5% year-over-year compared to Q2 2024. Operating income came in at $-819,000.

Over the past 8 quarters, HARVARD BIOSCIENCE INC has demonstrated a growth trajectory, with revenue expanding from $23M to $85M. Investors analyzing HBIO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

HBIO Dividend Yield and Income Analysis

HARVARD BIOSCIENCE INC (HBIO) does not currently pay a dividend. This is common among smaller companies in the Measuring And Control Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Technology dividend stocks may want to explore other Technology stocks or use the stock screener to filter by dividend yield.

HBIO Momentum and Technical Analysis Profile

HARVARD BIOSCIENCE INC (HBIO) has a momentum factor score of 53/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 36/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 62/100 reflects moderate short selling activity.

HBIO vs Competitors — Technology Sector Ranking and Peer Comparison

Within the Technology sector, HARVARD BIOSCIENCE INC (HBIO) ranks #222 out of 584 stocks based on the Blank Capital composite score. This places HBIO in the upper half of all Technology stocks in our coverage universe. Key competitors and sector peers include IHS Holding Ltd (IHS) with a score of 55.0/100, VERISIGN INC/CA (VRSN) with a score of 56.0/100, ESCO TECHNOLOGIES INC (ESE) with a score of 51.7/100, CareCloud, Inc. (CCLD) with a score of 46.9/100, and MMTec, Inc. (MTC) with a score of 47.4/100.

Comparing HBIO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full HBIO vs S&P 500 (SPY) comparison to assess how HARVARD BIOSCIENCE INC stacks up against the broader market across all factor dimensions.

HBIO Next Earnings Date

No upcoming earnings date has been announced for HARVARD BIOSCIENCE INC (HBIO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy HBIO? — Investment Thesis Summary

The quantitative profile for HARVARD BIOSCIENCE INC suggests caution. The quality score of 35/100 flags below-average profitability. The value score of 10/100 indicates premium valuation. High volatility (stability score 20/100) increases portfolio risk.

In summary, HARVARD BIOSCIENCE INC (HBIO) earns a Reduce rating with a composite score of 37.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on HBIO stock.

Related Resources for HBIO Investors

Explore more research and tools: HBIO vs S&P 500 comparison, top Technology stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare HBIO head-to-head with peers: HBIO vs IHS, HBIO vs VRSN, HBIO vs ESE.